The room smells faintly of eucalyptus. A receptionist taps the tablet and says the scan takes under a minute. You stand on a platform while half a million tiny sensors prepare to map your insides.
I write about tech and medicine enough to know when an idea is a PR stunt and when it might actually remap an industry. You’re going to want to read the small print here, because Midjourney’s latest pivot reads like a sleek bet on health data—and your body is the asset.
The MRI is loud, narrow, and often unavoidable.
Most people I know have a story about an MRI: the claustrophobia, the drumbeat of noise, the long wait for results. Midjourney is pitching a consolation: a scanner that uses ultrasonic echoes from thousands of tiny sensors to render a 3-D map in seconds.
The company’s blog describes stepping into “a shallow pool of golden light” while rings of sensors ping your organs. They promise terabytes of data per second, and a ring of roughly half a million grain-sized sensors firing ultrasonic waves from every angle. The claim is simple: more angles, more data, clearer imagery.
Is Midjourney building a medical scanner?
Yes—and no. Midjourney published a blog post outlining an R&D program for an ultrasonic body scanner and a plan to submit early test results to the FDA. But the announcement was aspirational: it laid out the concept, the intended user experience, and some engineering challenges, not a validated clinical device with regulatory clearance.
The technology promises speed; the hard work is the math.
Engineers I spoke with at med-tech firms like GE Healthcare and Siemens emphasize one blunt fact: collecting waves is one thing; turning noisy echoes into medically useful images is another.
Midjourney admits the project faces a “major computational task”—transforming terabytes of noisy signals into static, diagnostic images. I’ve seen teams spend years on reconstruction algorithms, training models with labeled scans and clinical oversight. Midjourney’s advantage is familiarity with large models and generative systems, but healthcare-grade imaging requires validation, explainability, and careful monitoring.
How does Midjourney’s scanner compare to an MRI?
MRIs already give high-resolution anatomical and functional detail; they are proven in diagnosis and have established clinical workflows. Midjourney’s device is pitched as faster, less invasive, and more comfortable. But the big questions remain: diagnostic sensitivity, specificity, safety of high-rate ultrasound exposure, and whether reconstructed images can meet radiologists’ standards.
San Francisco is getting a spa with pools of light—marketing meets medicine.
The company says it will open a 24/7 spa in downtown San Francisco before the end of next year, complete with hot tubs, cold plunges, and “cozy rooms with pools of golden light which softly scan your body.”
I’ve walked into luxury wellness spaces before; they’re designed to lower your guard. Midjourney frames the scans as a pleasant side effect of relaxation. That framing turns a diagnostic act into a consumer experience, and it raises immediate ethical and privacy flags: who owns the data, who can access it, and how will it be stored?
The proposal reads like a lighthouse sweeping the shore: a bright signal that promises safety while revealing everything in its beam.
When will the Midjourney spa open?
The company set a target: downtown San Francisco by the end of next year, with plans to expand to other cities starting in 2028. Those timelines are optimistic for any device that plans FDA submissions and clinical testing before general use.
Regulation, privacy, and the business model all matter.
Startups can promise experiences; regulators demand evidence. Midjourney’s path includes submitting early data to the FDA to seek clearance for devices with “increased capabilities.”
That process usually involves preclinical testing, pilot clinical studies, and rigorous performance benchmarks against established imaging modalities. On top of that, the idea of collecting “as many megabytes per second per dollar of information about your body” invites a business model based on data aggregation. You should ask: will anonymization hold? Who profits from scans that become part medical record and part consumer dataset?
The founder’s background in generative visuals gives Midjourney credibility in large-scale modeling, and the company name carries cultural weight after years of AI imagery. But credibility in art and credibility in medical devices are separate currencies. The FDA, clinicians, and privacy advocates will want numbers, not metaphors.
The spa’s golden pools promise the calm of a cathedral of light.
I’ve told stories where technology redefines what we tolerate from medicine—faster answers, new conveniences, and new trade-offs. You can admire a shorter scan and still demand the same standards that protect patients. Who decides when your next wellness visit becomes a medical record, and who benefits when that record is monetized?
Is Midjourney offering a legitimate leap in diagnostic imaging or repackaging surveillance as serenity?